Will health insurance cover Evrysdi?

Health insurance coverage for Evrysdi may vary depending on the specific insurance plan. It is recommended to contact your insurance provider to determine if Evrysdi is covered and what out-of-pocket expenses may be involved.

Evrysdi is a medication that is approved for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older. SMA is a genetic disorder that affects the muscles and can cause weakness and difficulty with movement.

Evrysdi works by increasing the production of a protein called survival motor neuron (SMN) that is essential for the proper functioning of motor neurons. By increasing SMN levels, Evrysdi helps improve muscle function in individuals with SMA.

Common side effects of Evrysdi may include fever, diarrhea, rash, mouth ulcers, and upper respiratory tract infection. It is important to discuss any potential side effects with your healthcare provider.

Yes, Evrysdi is approved for use in children as young as 2 months of age with spinal muscular atrophy (SMA). However, the safety and effectiveness of Evrysdi in pediatric patients with SMA type 1 (the most severe form of the condition) have not been established.

Evrysdi is taken orally as a liquid suspension. The dosage and administration instructions should be followed as prescribed by your healthcare provider.